

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EPS Creative Health Technology Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3860)

PROFIT WARNING

This announcement is made by EPS Creative Health Technology Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders (the “**Shareholders**”) and the potential investors of the Company that, based on the preliminary review of the latest unaudited consolidated management accounts of the Group for the five months ended 31 August 2026 and the information currently available to the Company, the Group is expected to record an increase in loss after taxation in the range of approximately HK\$8 million to HK\$12 million for the six months ended 30 September 2026 (the “**Period**”) as compared to the same period in 2025. The expected increase in loss for the Period as compared to the same period in 2025 was primarily attributable to a decline in revenue for IRO with CRO services business driven by highly intense market competition, and a decrease in gross profit for healthcare and medicated products business, which suffered from rising procurement costs and low-price inventory clearance. During the Period, the Group’s garment business is also expected to incur a segment loss of approximately HK\$2 million, which is similar to that of the corresponding period in 2025, in view of the challenging market environment.

The information contained in this announcement is only based on a preliminary assessment by the Board of the unaudited consolidated management accounts of the Group for the five months ended 31 August 2026 and the information currently available to the Board, which have not been audited or reviewed by the auditor of the Company nor reviewed by the audit committee of the Company, and is subject to adjustment where appropriate. Details of the financial information and performance of the Group for the Period will be disclosed in the interim results announcement of the Company, which is expected to be published in late November 2026 in accordance with the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
EPS Creative Health Technology Group Limited
Miyano Tsumoru
Executive Director

Hong Kong, 2 October 2026

As at the date of this announcement, the executive Directors are Mr. Washikita Kenichiro, Mr. Miyano Tsumoru, Mr. Narumi Shoichi, Ms. Du Yao, Mr. Liang Fei and Mr. Kitagawa Rikiya; the non-executive Director is Mr. Uematsu Takahiro; and the independent non-executive Directors are Mr. Chan Cheuk Ho, Mr. Choi Koon Ming, Mr. Saito Hironobu and Ms. Zhang Cuiping.